KURA
Kura Oncology, Inc.Company with tickers: KURA
CIK
1422143
CUSIP
50127T109
Shares Outstanding
88,774,365
Website
https://www.kuraoncology.com
13F Activity (30d)
4 filings
3 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael J. Vasconcelles, M.D. | Class III director | Appointed | 2026-06-04 |
| Mary T. Szela | Class III director | Appointed | 2026-06-04 |
| Diane Parks | Class III director | Appointed | 2026-06-04 |